DepoMed (DEPO) Bullish Expectations; Cheniere Energy (LNG) Under Carl Icahn Umbrella


Shares of DepoMed Inc. (Nasdaq:DEPO) climbed more than 6.5% in the extended session Monday after the company delivered stronger-than-expected quarterly financial results and raised its 2015 revenue guidance to the range of $336 million to $348 million from the previously reported revenue guidance range of $320 million to $340 million

For the third quarter 2015, DepoMed posted net sales of $105 million and non-GAAP net icome of $24.89 million or $0.33 per share, exceeding the Capital IQ Consensus Estimate of $0.21 earnings per share on revenues of $102.28 million for the period

DEPO stock closed the regular session at $20.11, up $0.24 (or +1.21%), with a total volume of 2,048,788 shares traded during the day

Depomed, a specialty pharmaceutical company that commercializes products for pain and neurology related disorders, has $60.37M Shares Outstanding, Market Capitalization (intraday) of $1.21B and DEPO stock 52-week range is between $14.00 and $33.74 per share



According to a regulatory filing made with the Securities and Exchange Commission (SEC), funds controlled by billionaire activist investor Carl Icahn now hold 29,546,241 shares of Cheniere Energy, Inc. (NYSEMKT:LNG), or about 12.52% stake in the company, representing an increase from the 12.07% stake disclosed in an SEC filing on October 1st, 2015

Cheniere recently reported a net loss of ($297.8) million, or ($1.31) per share for the third quarter 2015

LNG stock finished at $46.19, down $0.21 (or -0.45%) on Monday’s trading session

Cheniere Energy, an energy company primarily engaged in LNG-related businesses, has 236.57M Shares Outstanding, Market Capitalization (intraday) of $10.93B and LNG stock one-year range is $43.96 – $82.32 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at